focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Sale

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') First Commercial Sale of Synature Product ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its Progeny(R)venture company Synature, which offers a new and innovative approach to onlinemarketing, has secured its first commercial sale with a leading player in theworld's most active markets for package holidays and other leisure travelservices. Together they have launched Holiday Matchmaker, a new way for holidaybuyers to find their ideal destination based on recommendations from like-mindedpeople. This is the first commercial sale of Synature's unique patentedtechnology qubox(TM). Holiday Matchmaker utilises Synature's "attitudinal matching" approach todevelop principles derived from constructivist psychology to measure a person'sfeelings on a particular subject - in this case holidays - and thereby connectweb users to relevant content. Feelings are measured in a fun, engaging wayusing Synature's unique proprietary technology qubox(TM), to complete an online'questionnaire'. The results are then processed with state-of-the-art patternrecognition algorithms, derived from research at the University of Cambridge,UK, to provide personalised recommendations. Thousands of users of the customer's website have taken part in a surveyspecifically designed for the launch of the Holiday Matchmaker, which providesrecommendations based entirely on the opinions of an "online jury". The recommendation system uses a scientific measure of like-mindedness to ensurea client's holiday suggestions come from people with compatible views. Thesystem provides suggestions in multiple categories, including "essential picks","dream holidays" and "quirky choices". John Woods, Chief Executive of Synature, commented: "The Holiday Matchmaker is a new way of searching for a travel product. Itsresults are based on the unbiased opinions of a like-minded peer group. Whereasprevious generations of search and personalisation technology have struggledwith complex products such as travel, our approach built on like-mindedness andusing the power of the social internet takes this product complexity in itsstride. We can even tackle hypothetical questions, such as the idea ofrecommending a 'dream holiday'." Andrew Newland, Chief Executive of ANGLE plc, added: "We are delighted that Synature has secured its first commercial sale with aleading player in the holiday market. The Synature qubox(TM)technology has wideapplication in many online markets and we look forward to further developments." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Synature +44 (0)8701 909550John Woods, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors: About Synature Synature (www.synature.com) was created by ANGLE in early 2005 to commercialiseintellectual property developed by a Cambridge-based team which offers a newapproach to online target marketing. The company has developed this"attitudinal matching" approach into an ASP service offering advanced socialsearch functionality usable by all types of website including e-commerce, socialnetworks, portals and content sites. About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.